TIL Therapy – Encouraging Results for Treating Metastatic Lung Cancer
Scientists at the H. Lee Moffitt Cancer Center in Florida are investigating the potential for using tumor infiltrating lymphocytes (TIL therapy) in the fight against metastatic lung cancer. [1] PD-1 immune checkpoint inhibitors and CAR T cell therapies are some of the most promising cancer treatments developed in recent years to help fight aggressive cancers. […]
Anti-PD1 Cancer Treatment – Excellos T Cells Aid Evaluation
Scientists at GSK in Waltham, Massachusetts, are using Excellos-sourced T cell starting material for their preclinical evaluation of an anti-PD1 antibody. Programmed Cell Death Protein-1 (PD-1) is a transmembrane protein recognized for its role in regulating T cell activity. PD-1 and its analogs are often called “checkpoint inhibitors” because they act as a checkpoint to […]
And Blast off……Excellos Launches into (Cell Therapy) Space
The launch of Excellos now brings scientific and cell manipulation expertise to support the development of investigational cellular products through to commercialization, by leveraging the San Diego Blood Bank (SDBB) and its network of collection centers.
T Cell Immunotherapy – Excellos Cellular Material Helps Boost Development
T cell immunotherapy is a promising and relatively new field of medicine focused on tailoring a person’s own immune cells to fight disease more effectively. The field has enjoyed early success in the area of cancer immunotherapy, most notably the development of chimeric antigen receptor (CAR) T cells designed to express antigens that specifically target […]
Cell and Gene Therapy Industry – Excellos Launches to Accelerate Innovation
Founded by an Experienced Management Team and Built on the Reach and Infrastructure of the San Diego Blood Bank Cell and Gene Therapy CDMO San Diego, CA: Excellos, Incorporated, a cell therapy Contract Development and Manufacturing Organization (CDMO), announces its official corporate launch and closing of $15M in growth funding from Telegraph Hill Partners (THP). […]